Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 6901-6911

  Wang, Yong Sheng ^a   Li, Dan ^a   Shi, Hua Shan ^a   Wen, Yan Jun ^a   Yang, Li ^a   Xu, Ning ^a   Chen, Xian Cheng ^a   Chen, Xiang ^a   Chen, Ping ^a   Li, Jiong ^a   Deng, Hong Xin ^a   Wang, Chun Ting ^a   Xie, Gang ^a   Huang, Shan ^a   Mao, Yong Qiu ^a   Chen, Li Juan ^a   Zhao, Xia ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR IMMUNITY;

ALPHA-DEFENSINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYTOKINES; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS; SPLEEN; TRANSFECTION;

EID: 72549092934     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0484     Document Type: Article

References (53)

1. Ganz T, Lehrer RI. Defensins. Curr Opin Immunol 1994;6:584-589
2. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005;6:551-557
3. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003;3: 710-720 (Pubitemid 41070812)
4. Wu Z, Cocchi F, Gentles D, et al. Human neutrophil α-defensin 4 inhibits HIV-1 infection in vitro. FEBS Lett 2005;579:162-166 (Pubitemid 40023390)
5. Barker E, Reisfeld RA. A mechanism for neutrophil- mediated lysis of human neuroblastoma cells. Cancer Res 1993;53:362-367 (Pubitemid 23031850)
6. Lichtenstein A, Ganz T, Selsted ME, Lehrer RI. In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood 1986;68:1407-1410
7. McKeown ST, Lundy FT, Nelson J, et al. The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. Oral Oncol 2006;42: 685-690 (Pubitemid 44094234)
8. Okrent DG, Lichtenstein AK, Ganz T. Direct cytotoxicity of polymorphonuclear leukocyte granule proteins to human lung-derived cells and endothelial cells. Am Rev Respir Dis 1990;141:179-185 (Pubitemid 20023402)
9. Van Wetering S, Mannesse-Lazeroms SP, Dijkman JH, Hiemstra PS. Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. J Leukoc Biol 1997;62:217-226 (Pubitemid 27380794)
10. Bateman A, Singh A, Jothy S, Fraser R, Esch F, Solomon S. The levels and biologic action of the human neutrophil granule peptide HP-1 in lung tumors. Peptides 1992;13:133-139
11. Hubert P, Herman L, Maillard C, et al. Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre) neoplastic lesions formed in vitro and transplanted in vivo. FASEB J 2007;21:2765-2775
12. Mizukawa N, Sugiyama K, Kamio M, et al. Immunohistochemical staining of human α-defensin-1 (HNP-1), in the submandibular glands of patients with oral carcinomas. Anticancer Res 2000;20:1125-1127 (Pubitemid 30240686)
13. Muller CA, Markovic-Lipkovski J, Klatt T, et al. Human α-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation. Am J Pathol 2002;160:1311-1324 (Pubitemid 34411635)
14. Albrethsen J, Moller CH, Olsen J, Raskov H, Gammeltoft S. Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer. Eur J Cancer 2006;42:3057-3064 (Pubitemid 44679822)
15. Melle C, Ernst G, Schimmel B, et al. Discovery and identification of α-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 2005;129:66-73. (Pubitemid 41002043)
16. Xu N, Wang YS, Pan WB, et al. Human α-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice. Mol Cancer Ther 2008;7:1588-1597
17. Territo MC, Ganz T, Selsted ME, Lehrer R. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989;84: 2017-2020
18. Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000;68:9-14. (Pubitemid 30679730)
19. Tani K, Murphy WJ, Chertov O, et al. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int Immunol 2000;12:691-700. (Pubitemid 30248902)
20. Lillard JW, Jr., Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci U S A 1999;96: 651-656 (Pubitemid 29061263)
21. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 2004;113:774-783 (Pubitemid 38544171)
22. Fushimi T, Kojima A, Moore MA, Crystal RG. Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 2000;105:1383-1393 (Pubitemid 30322404)
23. Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP. Dendritic cells infiltrating tumors cotransduced with granulocyte/ macrophage colony-stimulating factor (GMCSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 1999;190:125-133 (Pubitemid 29330129)
24. Ma XT, Xu B, An LL, et al. Vaccine with β-defensin 2-transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses. Cancer Res 2006;66: 1169-1176
25. Wang YS, Wang GQ, Wen YJ, et al. Immunity against tumor angiogenesis induced by a fusion vaccine with murine β-defensin 2a nd mFlk-1. Clin Cancer Res 2007;13:6779-6787
26. Biragyn A, Surenhu M, Yang D, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001; 167:6644-6653 (Pubitemid 33081603)
27. Chertov O, Michiel DF, Xu L, et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 1996;271:2935-2940 (Pubitemid 26055594)
28. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 2002;298:1025-1029
29. Yang SC, Hillinger S, Riedl K, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004;10:2891-2901
30. Rovere P, Vallinoto C, BondanzaA, et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998;161: 4467-4471 (Pubitemid 28492012)
31. Heller LC, Coppola D. Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect. Gene Ther 2002;9:1321-1325
32. Nguyen LT, Atobe K, Barichello JM, Ishida T, Kiwada H. Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes. Biol Pharm Bull 2007;30:751-757 (Pubitemid 46571005)
33. Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S. Cooperativity of Staphylococcus aureus enterotoxin B superantigen, major histocompatibility complex class II, CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000; 60:2710-2715 (Pubitemid 30318248)
34. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004;64:8604-8612
35. Economopoulou M, Bdeir K, Cines DB, et al. Inhibition of pathologic retinal neovascularization by α-defensins. Blood 2005;106:3831-3838
36. Chavakis T, Cines DB, Rhee JS, et al. Regulation of neovascularization by human neutrophil peptides (α-defensins): a link between inflammation and angiogenesis. FASEB J 2004;18:1306-1308
37. Pietra G, Mortarini R, Parmiani G, Anichini A. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. Cancer Res 2001;61:8218-8226 (Pubitemid 33091615)
38. Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999;190:1417-1426
39. Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003;200:255-268 (Pubitemid 36748035)
40. Bonnotte B, Crittenden M, Larmonier N, Gough M, Vile RG. MIP-3α transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. J Immunol 2004;173:4929-4935
41. Aarbiou J, Tjabringa GS, Verhoosel RM, et al. Mechanisms of cell death induced by the neutrophil antimicrobial peptides α-defensins and LL- 37. Inflamm Res 2006;55:119-127
42. Shaif-Muthana M, McIntyre C, Sisley K, Rennie I, Murray A. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res 2000;60:6441-6447 (Pubitemid 30952150)
43. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-434
44. Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov II, Petratchenko EV, Voitenok NN. Neutrophil α-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine Netw 2000;11:257-266
45. Kudo C, Yamashita T, Araki A, et al. Modulation of in vivo immune response by selective depletion of neutrophils using a monoclonal antibody, RP-3. I. Inhibition by RP-3 treatment of the priming and effector phases of delayed type hypersensitivity to sheep red blood cells in rats. J Immunol 1993;150:3728-3738
46. Kudo C, Yamashita T, Terashita M, Sendo F. Modulation of in vivo immune response by selective depletion of neutrophils using a monoclonal antibody, RP-3. II. Inhibition by RP-3 treatment of mononuclear leukocyte recruitment in delayed-type hypersensitivity to sheep red blood cells in rats. J Immunol 1993;150:3739-3746 (Pubitemid 23129755)
47. Larsen CG, Thomsen MK, Gesser B, et al. The delayed-type hypersensitivity reaction is dependent on IL-8. Inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody. J Immunol 1995;155:2151-2157
48. Humphreys IR, de Trez C, Kinkade A, Benedict CA, Croft M, Ware CF. Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J Exp Med 2007;204:1217-1225 (Pubitemid 46798163)
49. Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4 (+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001; 103:449-457 (Pubitemid 32744391)
50. Valore EV, Martin E, Harwig SS, Ganz T. Intramolecular inhibition of human defensin HNP-1 by its propiece. J Clin Invest 1996;97: 1624-1629 (Pubitemid 26105473)
51. Albrethsen J, Bogebo R, Gammeltoft S, Olsen J, Winther B, Raskov H. Upregulated expression of human neutrophil peptides 1, 2and 3 (HNP 1- 3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 2005;5:8. (Pubitemid 40180311)
52. Lichtenstein A. Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J Clin Invest 1991;88:93-100.
53. Nishimura M, Abiko Y, Kurashige Y, et al. Effect of defensin peptides on eukaryotic cells: primary epithelial cells, fibroblasts and squamous cell carcinoma cell lines. J Dermatol Sci 2004;36:87-95. (Pubitemid 39424131)